Support Advancements in Research


or Use Our Simple Online Form to Give Us Feedback

We welcome your comments and feedback. Please include contact information if you'd like a response.

Did you find this page helpful?

If you would like a response, please include your contact information.

Evangelos S. Gragoudas, M.D.

Harvard Medical School

Charles Edward Whitten Professor of Ophthalmology, Department of Ophthalmology

Massachusetts Eye and Ear

Director, Retina Service
Co-Director, Laser Laboratory
Co-Director, Retina Research Institute
Co-Director, Angiogenesis Laboratory
Senior Scientist

Center Affiliations

Research Summary

Dr. Gragoudas played a pivotal role in the development of proton bean therapy (PBT) for uveal melanoma, and performed both preclinical studies and the first clinical studies in patients. He continues to refine PBT and has taken a multidisciplinary approach to developing new strategies for managing uveal melanoma.Studies initiated in the early 1990s with Dr. Joan Miller produced a breakthrough for patients with wetAMD: photodynamictherapy (PDT) with verteporlin (VISudyne®). He and his colleagues identified the important role of vascular endothelial growth factor (VEGF) in ocular neovascularization, which formed the scientific basis for the present antiangiogenic treatments for neovascular AMD and other intraocular vascular diseases.

Photo of Evangelos S. Gragoudas, M.D.

Evangelos S. Gragoudas, M.D.


Mass. Eye and Ear

243 Charles Street

Boston, MA 02114

T: 617-573-3515

F: 617-573-3678


For patient inquiries, please visit
» Clinician Profile